Healthy Volunteers
Conditions
Brief summary
This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose sequential group study in healthy participants. This study consists of three parts: Part A (single dose escalation, SAD) , Part B (food effect, FE) and Part C (relative bioavailability, BA).
Interventions
DRUGDZD9008
In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
DRUGPlacebo
In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
Sponsors
Dizal Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants must be able to understand the nature of the trial and provide a signed and dated, written informed consent form before any study-specific procedures, sampling and analyses. * Provision of signed and dated written Optional Genetic Research informed consent prior to collection of samples for optional genetic research. * Healthy male or female participants aged 18 to 60 years (inclusive), with BMI 18.0 to 30.0 kg/m2 (inclusive). Body weight: ≥ 55 kg for male, ≥ 45 kg for female. * Healthy participants defined as the absence of acute or chronic clinically significant deviations from normal in medical history, physical examination, visual assessment, electrocardiogram (ECG), and clinical laboratory determinations at screening. * Participants must agree to practice effective contraception. * Normal baseline PFTs (≥ 80% predicted normal for spirometry, lung volumes). * Normal baseline ECG (QTcF \< 450 msec, PR \< 210 msec). * Non-smoker (not smoked within 3 months). * Liver biochemistry parameters: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN * Adequate organ function including hepatic, renal, cardiac, visual and bone marrow function as determined by the investigator.
Exclusion criteria
* Ongoing or prior pulmonary disease including asthma, chronic obstructive pulmonary disease, interstitial lung disease and pneumonitis including but not limited to drug-related pneumonitis. * Women who are breast feeding. * Positive pregnancy test prior to study entry. * History of malignancy of any type, with the exception of the following: surgically excised non-melanomatous skin cancers more than 5 years prior to receiving IP. * A history of additional risk factors for TdP (e.g. heart failure, hypokalemia, family history of Long QT syndrome). * No prior history of atrial fibrillation within 6 months prior to first dosing of DZD9008 * Manifestations of malabsorption due to prior GI surgery, GI disease, or for an unknown other reason that may affect the absorption of DZD9008-. Pulmonary infections or other active infection within 30 days of informed consent * History of bleeding disorder (including hemophilia, Von Willebrand disease, etc), history of stroke or intracranial haemorrhage within 6 months before study drug administration. * Judgement by the investigator that the participant is not likely to comply with study procedures, restrictions and requirements. * Positive serology or a known history of hepatitis B virus (HBV), hepatitis C virus (HCV), HIV. * Resting blood pressure \> 140/90 mmHg at screening . * Resting pulse rate \< 45 beats per minute. * History of severe allergy or hypersensitivity reaction or ongoing allergy or hypersensitivity reaction, as judged by investigator, or history of hypersensitivity to EGFR/HER2/BTK inhibitors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) | up to 14 days after study drug administration | To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants. |
| Number of participants with clinically significant laboratory assessment abnormalities | up to 14 days after study drug administration | To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants. |
| Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities | up to 14 days after study drug administration | To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants. |
| Number of participants with clinically significant abnormalities in LVEF | up to 14 days after study drug administration | To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants. |
| Number of participants with clinically significant abnormalities in FEV1% | up to 14 days after study drug administration | To assess the safety and tolerability of DZD9008 following oral administration of single ascending doses in healthy adult participants. |
Secondary
| Measure | Time frame |
|---|---|
| Apparent volume of distribution (Vz/F) | up to 10 days after study drug administration |
| Maximum plasma concentration (Cmax) of DZD9008 | up to 10 days after study drug administration |
| Terminal elimination half-life (t1/2) | up to 10 days after study drug administration |
| Mean residence time (MRT) | up to 10 days after study drug administration |
| Time to reach maximum plasma concentration (tmax) | up to 10 days after study drug administration |
| Area under the concentration-time curve from time 0 (pre-dose) to the time of the dosing interval (AUC0-t) | up to 10 days after study drug administration |
| Area under the concentration-time curve from time 0 to infinity (AUC0-inf) | up to 10 days after study drug administration |
| Apparent total plasma clearance (CL/F) | up to 10 days after study drug administration |
Countries
United States
Outcome results
None listed